Autism spectrum disorders (ASD) are a heterogeneous group of disorders which have complex behavioural phenotypes. Although ASD is a highly heritable neuropsychiatric disorder, genetic research alone has not provided a profound understanding of the underlying causes. Recent developments using biochemical tools such as transcriptomics, proteomics and cellular models, will pave the way to gain new insights into the underlying pathological pathways. This review addresses the state-of-the-art in the search for molecular biomarkers for ASD. In particular, the most important findings in the biochemical field are highlighted and the need for establishing streamlined interaction between behavioural studies, genetics and proteomics is stressed. Eventually, these approaches will lead to suitable translational ASD models and, therefore, a better disease understanding which may facilitate novel drug discovery efforts in this challenging field.
Introduction
Autism spectrum disorders (ASDs) are a range of clinically heterogeneous neurodevelopmental conditions consisting mainly of autistic disorder (AD), Asperger's syndrome (AS) and pervasive developmental disorder not otherwise specified (PDD-NOS). In addition, other conditions included in ASDs are childhood disintegrative disorder (CDD) and the gene disorders such as Rett's syndrome (RTT), fragile X syndrome (FXS) and tuberous sclerosis (TSC). ASDs are characterized by impairments in social interaction and communication, along with the presence of restricted and repetitive behaviours (Veenstra-Vanderweele et al., 2004) . The core behavioural abnormalities of the affected individuals are often accompanied by medical co-morbidities such as epilepsy, gastrointestinal obstructions, motor deficits, sleep disturbances, cognitive deficits, mental retardation (IQ < 70) or attention deficit hyperactivity disorder (ADHD) (Levy et al., 2009; Bauman, 2010; Maski et al., 2011) .
In the last two decades, the number of reported ASD cases has increased from 1 in 2000-2500 (Fombonne and du Mazaubrun, 1992) , to 1 in 88. This could be due to environmental factors, a broadening of diagnostic criteria, increased awareness of the disorder, improved diagnostic methods or any of these in combination. In most ASD diagnoses, a skewed gender ratio has been found, with increased prevalence in males at a ratio of 4:1 (males:females) or even higher (Scott et al., 2002; Williams et al., 2008) . One hypothesis that takes into account the gender effect and the cognitive style of ASD is the 'extreme male brain theory'. This describes ASD as an extreme variant of male intelligence and is based on research describing sex differences in cognition (Baron-Cohen, 2002 Findings in support of this theory include the facts that the systemising quotient (SQ) is higher in non-ASD males compared to non-ASD females, and both males and females with ASD show higher scores than non-ASD males. Moreover, the empathy quotient (EQ) is higher in non-ASD females than for non-ASD males, and both males and females with ASD score even lower than non-ASD males (Baron-Cohen, 2002) .
Methods for diagnosing ASDs include the Autism Diagnostic Observation Schedule (ADOS, (Lord et al., 2000) ) and the Revised Autism Diagnostic Interview (ADI-R, (Lord et al., 1994) ), which are both based on Diagnostic and Statistical Manual (DSM)-IV-R criteria. However, these methods only assess symptomatic changes in behaviour and are based on subjective human observations (Noterdaeme et al., 2002; Akshoomoff et al., 2006) . In addition, ASD diagnosis distinguishes idiopathic ASD (primary ASD) from symptomatic ASD (secondary ASD) (Hara, 2007) . In idiopathic ASD, no specific aetiology is present, as in genetic or neurological disorders linked to ASD, such as FXS, TSC and RTT. Individuals with idiopathic ASD often show only abnormal behaviour and their cognitive level is more likely to be preserved as in high functioning autism and Asperger's syndrome cases (Trimble and Schmitz, 2011) . Although the underlying cause of idiopathic ASD remains unexplained, it is thought that genetic susceptibility and environmental triggers may be involved (Dissanayake et al., 2009) . In contrast, symptomatic ASD is often associated with mental retardation and abnormal neurological findings (Trimble and Schmitz, 2011) . Genetic studies have shown that more genes appear to be associated with ASD forms which are co-morbid with severe mental retardation (symptomatic ASD) compared to forms of ASD with mild or no mental retardation (idiopathic ASD) (Cook and Scherer, 2008; Kaufman et al., 2010) . Moreover, the diagnosis of ASD is complicated by the heterogeneity of symptoms in terms of severity and expression type. It is thought that such heterogeneous clinical phenotypes can share common pathways and result in a phenotypic overlap (Sacco et al., 2010) . Therefore, the inclusion of adequate control groups for any interpretation is essential. The majority of biological research has not attempted to disentangle the problem of which genes or biological markers are associated with specific ASD subtypes or ASD with specific co-morbidities, such as severe mental retardation.
Existing treatments for ASD do not alleviate core deficits, but rather treat the observed behavioural symptoms (Canitano and Scandurra, 2011; Veenstra-VanderWeele and Blakely, 2012) . To date, the only FDA-approved drug treatments for ASD are risperidone and aripiprazole, which are both atypical antipsychotics and, therefore, are used in the treatment of other neuropsychiatric disorders, such as schizophrenia (Erickson et al., 2010) . In order to increase the accuracy of diagnoses and develop better ASD treatments, there is a substantial need for objective diagnostic methods and thus for biomarkers.
ASD hypotheses
One of the most common neuroanatomical features of ASD is macrocephaly, with an incidence of 80% occurring between birth and 2 yr of age (Lainhart et al., 1997) . Studies suggest that this is mediated by enhanced anabolic activity in the central nervous system (CNS), reflected by increased levels of brain-derived neurotrophic factor (BDNF) (Ray et al., 2011) . Moreover, children with ASD showed impaired CNS circulation, which leads to hypoxia (Ryu et al., 1999) in brain regions such as the temporal lobe (Ichim et al., 2007) . In general, abnormal brain connectivity is assumed to contribute to the pathology of ASD, by hindering the flow of information in the brain (Kana et al., 2012) . This is most likely due to localized synaptic loss or decreases in synapse formation (Sporns et al., 2000) .
The major difference between symptomatic and idiopathic ASD is that the genetic cause of symptomatic ASD is known, such as FXS, TSC and RTT, while for idiopathic ASD the aetiology remains unknown (Dissanayake et al., 2009; Thomas and Klaper, 2012) . The aetiology of idiopathic ASD is thought to involve both genetic and environmental components. ASD has a strong heritability, although potential risk genes have been identified in 20-25% of cases (Miles, 2011 ) by genome-wide association studies (GWAS), genomewide linkage studies, copy number variation studies and quantitative trait loci (QTL) analysis (Abrahams and Geschwind, 2008) . The most significant progress in the identification of genetic causes in ASD has come from identifying known genetic mutations, and through association with other disorders that can predispose individuals towards development of ASD. In addition, cytogenetic abnormalities have been found, comprising effects on virtually all chromosomes, in 5% of children with ASD in studies using high-resolution karyotype analysis or fluorescence in situ hybridization (FISH) (Reddy, 2005; Vorstman et al., 2006; Lintas and Persico, 2009; Miles, 2011) . The most frequent chromosomal aberrations observed in ASD include the maternal duplication of chromosome 15q11-13 (Abrahams and Geschwind, 2008 ) and a 600 kb microdeletion/microduplication at 16p11.2, each occurring in approximately 1% of ASD cases (Cook and Scherer, 2008) . Genes that are most often implicated in ASD are MET tyrosine kinase, neuroligins and neurexin which have been linked to effects on cognition (Sudhof, 2008) . More recent genetic investigations in ASD have focused on copy-number variations (CNVs), which may occur both de novo and in families with a history of ASD (Pinto et al., 2010; Silverman et al., 2010; Nomura and Takumi, 2012 ). An updated overview on genetic abnormalities in ASD is available using the Autism Chromosome Rearrangement Database (http://projects.tcag.ca/autism) (Marshall et al., 2008) , SFARI gene (https://://gene.sfari.org/autdb/ Welcome/do), and Autism Genetic Database (http:// wren.bcf.ku.edu/).
Although ASD is one of the most highly heritable neuropsychiatric disorders (Smalley et al., 1988; Monaco and Bailey, 2001) , none of the discovered ASD risk genes, alone or in combination, are strong enough to predict the extent to which ASD symptoms will be manifested. In most cases, it is now thought that complex gene-environment interactions and epigenetic modifications are involved. For example, exposure to rubella during the first trimester might contribute to the development of ASD (Duszak, 2009 ). In addition, paternal and maternal age can significantly increase the risk of developing ASD, especially with regards to the emergence of de novo mutations (Durkin et al., 2008; King et al., 2009; Hultman et al., 2011) . Recent studies have concluded that four major pathways are affected in ASD, which relate to immune dysregulation, oxidative stress, mitochondrial dysfunction and environmental toxin exposures (Rossignol and Frye, 2012b) .
Transcriptomics
Although genetic studies have been prominent in ASD research, a common underlying genetic effect has not yet been indicated. Therefore, a recent shift of ASD research is indicated from genetics to more omics-based profiling research. Due to this recent shift in research, studies investigating transcriptomic markers of ASD have been less frequent. However, an early cDNA microarray study of ASD brains showed dysregulation of hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits in the cerebellum (Purcell et al., 2001) . In general, AMPA receptors have their function in synaptic plasticity, which is implicated in ASD (Isaac et al., 2007; van Spronsen and Hoogenraad, 2010) . In addition, it has been shown that gamma-aminobutyric acid (GABA) receptor subunit β3 (GABRB3), a GABA receptor that is involved in signal transduction and propagation (Shiah and Yatham, 1998) , and reelin (Rln), which is involved in cell adhesion (DeSilva et al., 1997) , are the most commonly found transcriptomic markers (see Table 1 ). Interestingly, reelin is preferentially expressed in GABAergic interneurons (Impagnatiello et al., 1998) , which is an indication that the GABA signalling system is affected in ASD individuals. These most commonly found transcription markers are all important in synaptic plasticity and, together with the AMBA dysregulation finding, support the abnormal brain connectivity theory. The review by Voineagu describes a comparison between two transcriptomic studies of post-mortem ASD brains ( (Garbett et al., 2008) , showed a significant overlap between the brain development genes Abelson helper integration site 1 (AHI1) and Distall-less homeobox 1 (DLX1), which were both down-regulated, and the interferon response genes interferon induced transmembrane protein 2 and 3 (IFITM2 and IFITM3), which were up-regulated. AHI1 has been previously implicated in ASD (Alvarez Retuerto et al., 2008) and DLX1 is located in the 2q32 autism linkage peaks (Voineagu, 2012) IFITM proteins inhibit the entry of viruses to the host cells cytoplasm (Brass et al., 2009) . This is consistent with the role of inflammation in ASD (Depino, 2013) . In addition, one of Voineagu's key findings in peripheral tissue was the down-regulation of protein kinase C epsilon (PRKCE), a protein involved in anxiety behaviour and which modulates the response of GABA receptors to benzodiazepines (Hodge et al., 2002; Voineagu, 2012) . This, again, suggests that the GABA-system might be involved in ASD. These transcriptomic studies have only been carried out recently and, therefore, more investigations are needed to look for differences and validate changes at the transcriptional level in ASD subtypes and with regards to gender and age.
Proteomics
To date, there have only been a few studies which have investigated potential changes in protein levels in ASD patients. Proteomic profiling studies have looked at serum, plasma and post-mortem brain protein levels mainly using mass spectrometry (Corbett et al., 2007; Taurines et al., 2010) or multiplex immunoassay profiling (Schwarz et al., 2011) techniques. Table 2 shows the most frequently altered molecules which have been identified in ASD subjects compared to healthy volunteers. The strict frequency criteria used in the selection process resulted in identification of small molecules such as glutamate, serotonin, testosterone and glutathione, along with several proteins such as creatine kinase, ferritin and IL-8. However, relaxing the criteria resulted in identification of a higher proportion of proteins (Table 3) , such as BDNF, GFAP and reelin, which are involved in neuronal development, and eotaxin, CCL5 and ILs, which are associated with inflammation. As indicated in the transcriptomics data, effects on neuronal development and inflammation are the most common finding in ASD research, and these are likely to be associated with decreased myelination and impaired antioxidant and mitochondrial function. More specifically, a recurrent finding has been that of increased levels of molecules involved in synapse formation and integrity, such as BDNF and GFAP. However, a limitation of these studies was the lack of reproducibility, which could be due to the fact that none attempted to account for differences between diagnostically-defined subtypes or for the idiopathic or symptomatic forms. Compared to the study of other neurological diseases, in which proteomics investigations have already contributed to the understanding of the molecular biological defects (Junaid and Pullarkat, 2001) , the progress of such analyses in ASD has been relatively poor. Considering the potential insights already gained using this approach, further proteomic research in ASD guided by rigid patient selection criteria could help to overcome the lack of suitable biomarkers.
Neurochemical and neuronal modulators
Neurochemical investigations have proven to be useful in elucidating the underlying causes of mental disorders, such as schizophrenia. However, research into the neurochemistry of ASD is still at the preliminary stages. Table 1 . Overview of publications describing the most commonly found transcriptomic markers in autism spectrum disorders: gamma-aminobutyric acid receptor subunit β3 (GABRB3) and reelin (Rln). BA = Brodmann area, M = male, F = female
Marker
Effect N Brain area Article Gamma-aminobutyric acid receptor subunit β3 (GABRB3) ↔ 8 autism (16.4 yr±8.3; 6M, 2F; PMI 18.0 h±14.5), 13 controls (15.6 yr ± 6.5; 9M, 4F; PMI 15.0 h ± 5.6)
Anterior cingulate gyrus (ACG) (Thanseem et al., 2012) Gamma-aminobutyric acid receptor subunit β3 (GABRB3) 7 autism (17.4 yr ± 8.4; PMI 18.9 h ± 15.7), 8 controls (15.6 years ± 6.7; PMI 18.1 h ± 2.9)
Motor cortex (Thanseem et al., 2012) Gamma-aminobutyric acid receptor subunit β3 (GABRB3) BA 19, extrastriate visual cortex (Scoles et al., 2011) Reelin (Rln) 7 autism (6M, 1F; 28.9 yr ± 12.8; PMI 16.6 h ± 6.9), 9 controls (8M, 1F; 25.3 yr ± 5.4; PMI 21.0 h ± 5.0) Cerebellum (Fatemi et al., 2005) Reelin (Rln) 7 autism (6M, 1F; 28.9 yr ± 12.8; PMI 16.6 h ± 6.9), 6 controls (6M, 0F; 26.7 yr ± 5.7; PMI 20.5 h ± 3.6) BA 9, superior frontal cortex (Fatemi et al., 2005) Reelin (Rln) 8 autism (16.4 yr ± 8.3; 6M, 2F; PMI 18.0 h ± 14.5), 13 controls (15.6 yr ± 6.5; 9M, 4F; PMI 15.0 h ± 5.6) Anterior cingulate gyrus (ACG) (Thanseem et al., 2012) Reelin (Rln) ↔ 7 autism (17.43 yr ± 8.40; PMI 18.86 h ± 15.71) vs. 8 healthy controls (15.63 yr ± 6.74; PMI 18.13 h ± 2.90)
Motor cortex (Thanseem et al., 2012) Reelin (Rln) ↔ 8 autism (16.4 ± 8.3; 6M, 2F; PMI 18.0 h ± 14.5) vs. 9 healthy controls (15.6 yr ± 6.3; 6M, 3F; PMI 17.4 h ± 3.4) Thalamus (Thanseem et al., 2012 ) Table 2 . The most frequent findings in molecular profiling studies, carried out using serum, plasma or post-mortem brain tissue, although none of these indicated markers was also reproducible in the brain. Criteria for selection included requirements that the molecule must be mentioned by at least two different authors, using two or more techniques and should be changed (increased or decreased). Note that most of the robust changes were found for small molecules, with ferritin being the only robust protein identified 19 , 2 , 6 ↔ Plasma, serum, blood 19 (Schain and Freedman, 1961; Cook et al., 1988; Leventhal et al., 1990; Piven et al., 1991; Naffah-Mazzacoratti et al., 1993; László et al., 1994; Bouvard et al., 1995; Warren et al., 1996; Croonenberghs et al., 2000; Marazziti et al., 2000; Spivak et al., 2004; Connors et al., 2006; Cross et al., 2008; Hranilović et al., 2009; Correia et al., 2010; Anderson et al., 2012; El-Ansary et al., 2011; Mostafa et al., 2011 ) Testosterone 5 , 1 , 2 ↔ Serum 5 (Geier and Geier, 2006; Geier and Geier, 2007; Schwarz et al., 2010; Ruta et al., 2011 ) Glutathione oxidized (GSSG) 6 , 0 , 0 ↔ Plasma 5 (James et al., 2004; James et al., 2006; Geier et al., 2009a,b; James et al., 2009; Adams et al., 2011) Glutathione reduced (rGSH) 0 , 7 , 0 ↔ Plasma 5 (Geier and Geier, 2006; Geier et al., 2009a,b; Pastural et al., 2009; Adams et al., 2011; Al-Yafee et al., 2011) Sandman et al., 1991; Ernst et al., 1993; Bouvard et al., 1995; Willemsen-Swinkels et al., 1996; Tordjman et al., 1997) Brain-derived neurotrophic factor (BDNF) 4 , 4 , 5 ↔ Serum, plasma, CSF, brain 9 (Riikonen, 2003; Miyazaki et al., 2004; Hashimoto et al., 2006; Katoh-Semba et al., 2007; Correia et al., 2010; Schwarz et al., 2010; Al-Ayadhi, 2012; Ray et al., 2011; Thanseem et al., 2012 (Connolly et al., 1999; Trajkovski et al., 2004; Libbey et al., 2007; Bakkaloglu et al., 2008; Heuer et al., 2008; Spiroski et al., 2009; Williams et al., 2012 ) IgG1 3 , 0 , 3 ↔ Serum, plasma 4 (6 projects) (Trajkovski et al., 2004; Enstrom et al., 2009; Spiroski et al., 2009 ) IgG2 2 , 4 , 2 ↔ Serum, plasma 4 (8 projects) Spiroski et al., 2009 ) IgG3 1 , 0 , 4 ↔ Serum, plasma 4 (5 projects) (Trajkovski et al., 2004; Enstrom et al., 2009; Spiroski et al., 2009 ) IgG4 3 , 0 , 1 ↔ Serum, plasma 4 (Trajkovski et al., 2004; Enstrom et al., 2009; Spiroski et al., 2009 ) IgM 2 , 6 , 3 ↔ Serum, plasma 7 (11 projects) (Connolly et al., 1999; Trajkovski et al., 2004; Libbey et al., 2007; Bakkaloglu et al., 2008; Heuer et al., 2008; Spiroski et al., 2009 ) IL-1 receptor antagonist (IL-1RA) 1 , 0 , 2 ↔ Serum 2 (3 projects) (Singh et al., 1991 ; ) IL-10 5 , 0 , 4 ↔ Serum, plasma, brain 6 (9 projects) (Vargas et al., 2005; Saresella et al., 2009; Ashwood et al., 2010; Emanuele et al., 2010; Schwarz et al., 2010; Ashwood et al., 2011; Ashwood et al., 2011 Langwieser et al., 2010; Adams et al., 2011; Shimmura et al., 2011; Ecker et al., 2012; Schaevitz et al., 2012; Tirouvanziam et al., 2012; Yadav et al., 2012) and GABA- (Hogema et al., 2001; Fatemi et al., 2002 Fatemi et al., , 2009 Sekiguchi et al., 2009; El-Ansary et al., 2011) systems. In molecular profiling studies, the main altered molecules which regulate neuronal function are glutamate, which was shown to be increased, and the neuropeptide hormone oxytocin, which was decreased (Table 4 ). This has opened up the possibility of targeting these pathways as potential novel therapeutic approaches. Recently, mGluR antagonists and GABA agonists have been tested in both animal models and small-scale Phase II human trials for potential therapeutic benefits (Oberman, 2012) . In addition, oxytocin has been tested as a potential candidate for ASD treatment, and studies have been conducted with single-dose administration in adults and children diagnosed with high functioning autism or AS (Hollander et al., 2007; Andari et al., 2010; Guastella et al., 2010) . In a similar manner, long-term administration of oxytocin has been tested in ASD adults and adolescent boys (Anagnostou et al., 2012; Tachibana et al., 2013) . These investigations showed an increased social recognition in the subjects upon oxytocin treatment, which makes a good case for clinical application (Yamasue et al., 2012) . However, possible side effects of oxytocin administration can include uterine contractions and lactation in females (Di Simplicio et al., 2009) , impaired social bonding and, in some circumstances, aggression or other antisocial behaviour (Miller, 2013) .
Hormonal, inflammatory and growth factor modulators
As previously discussed, circulating oxytocin was found to be decreased (Modahl et al., 1998; Green et al., 2001; Al-Ayadhi, 2005 ) and the gonadal hormone testosterone was increased (Geier and Geier, 2007; Schwarz et al., 2010) in ASD patients. Studies investigating these hormone levels between male and female in ASD patients led to the identification of a gender effect, with increased testosterone levels found in female patients only (Baron- Cohen, 2002; Baron-Cohen et al., 2011) . Distinct sex-specific biomarker fingerprints for male and female were obtained in which circulating levels of hormones and growth factors, such as androgens, growth hormone and insulin-related molecules, were altered more in females, and inflammatory factors, such as cytokines and interleukins, were mainly altered in males (Schwarz et al., 2011) . In general, immune abnormalities have been observed in ASD indicative of increased astrocyte activity (Stubbs, 1995; Sweeten et al., 2004) and neuroinflammatory processes in the cerebral cortex, white matter and cerebellum (Vargas et al., 2005) . Furthermore, autoantibodies have been identified in children with ASD that are not detected in healthy controls (Ichim et al., 2007) , including antibodies against myelin basic protein (Singh et al., 1993 ), brain extracts (Silva et al., 2004; Singer et al., 2006) , Purkinje cells, gliadin extracted peptides (Vojdani et al., 2004) , neurotrophic factors (Kozlovskaia et al., 2000; Connolly et al., 2006) , neuronaxon filament and GFAP (Kozlovskaia et al., 2000) . It is suggested that premature birth and susceptibility genes stimulate the release of pro-inflammatory and neurotoxic molecules, which contribute to brain inflammation and ASD pathogenesis (Angelidou et al., 2012) . Clinical studies have shown that the use of anti-inflammatory agents might improve ASD symptomatology (Stefanatos et al., 1995; Shenoy et al., 2000; Wakefield et al., 2002) . Also, recent studies have identified changes in growth factors, such as neurotrophin-3 (NT-3) (Sajdel-Sulkowska et al., 2011; Tostes et al., 2012) and BDNF (Miyazaki et al., 2004; Hashimoto et al., 2006; Schwarz et al., 2010; Al-Ayadhi, 2012; Garcia et al., 2012) , which are all involved in neurodevelopment, synapse formation and neuronal survival.
Mitochondrial dysfunction and anti-oxidants
In addition to the neurochemical and inflammatory changes, mitochondrial/energy dysfunction has been linked to the ASD disease process (Geier et al., 2009b) . Such a dysfunction would be expected to have significant effects on the brain, since this organ is vulnerable to oxidative stress, resulting from restricted antioxidant capacity and high energy demand relative to other tissues of the body. A recent meta-analysis indicated a higher prevalence of mitochondrial dysfunction in ASD patients compared to the general population; however, no distinctions were made between the ASD subtypes (Rossignol and Frye, 2012a) . It has been hypothesized that these mitochondrial abnormalities are not the cause of the disorder, but rather an effect of altered calcium signalling, as shown in autism brain studies (Palmieri and Persico, 2010) . Links to oxidative stress have been identified in studies showing a decrease in the reduced form of glutathione (GSH) and the total amount of glutathione in both the brain (Chauhan et al., 2012; Rose et al., 2012a) and peripheral blood (Geier and Geier, 2006; James et al., 2006; Geier et al., 2009a, b; James et al., 2009; Al-Yafee et al., 2011) of ASD patients. However, the oxidized form of glutathione (GSSG) has been reported to be increased (James et al., 2004 (James et al., , 2006 (James et al., , 2009 Geier et al., 2009a; Adams et al., 2011; Chauhan et al., 2012; Rose et al., 2012a) . Moreover, Rose et al. showed that oxidative damage has an impact on the inflammatory response in the brain of autism patients, with an increase of 3-chlorotyrosine (3-CT) and a decrease in aconitase activity (Rose et al., 2012a ).
The future of molecular studies in ASD

Clinical studies
In human ASD studies, researchers have mainly relied on the availability of post-mortem brain tissue, CSF, plasma and serum samples. The main bottleneck in these studies has been the limitations in sample numbers of consistent high quality. As a consequence, such studies are often underpowered. Moreover, there have been few attempts to account for ASD subtypes, and the clinical description of subjects has been neglected in many studies. ASD research should aim to identify biomarkers that are uniquely associated with ASD subtypes, as these are likely to have distinct aetiologies. To date, no drug treatment has been proven to treat ASD symptoms effectively, and the need for novel drug targets remains high. The identification of novel targets will require the combined effort of scientists in multiple disciplines, and the establishment of bio-banks and international consortia to generate the molecular phenotypes underpinning the disease onset and progression. The establishment of the human signature of ASD will not only facilitate disease understanding, but will also offer the possibility to reverse translate the human signature to ASD preclinical models, such as rodent and cellular models, and to correlate the findings with clinical and behavioural readouts.
Animal models
Mouse models have been used frequently to examine mutations of specific alleles that have been associated with symptomatic ASD. This includes genes associated with the FXS, RTT and TSC forms of ASD, as well as those which have been implicated in idiopathic ASD (MET tyrosine kinase, neuroligins and neurexin) (Bishop and Lahvis, 2011) . Furthermore, the study of mice may be of high relevance to the core features of ASD as they are social animals displaying communication and social structures. It is important to note that ASD, especially idiopathic ASD, is marked by genetic and phenotypic heterogeneity, which makes it impossible to develop a single-gene mouse mutant that characterizes the disease. As a consequence, the development of mouse models specific for ASD has proven to be difficult. The development of rational models for ASD requires face validity (analogous to phenotypes, such as social deficits), construct validity (analogous to the cause of the human disorder, such as genetic mutations), and predictive validity (analogous in response to treatments) (Crawley, 2008) . Silverman et al. (2010) and Bishop et al. (Bishop and Lahvis, 2011) have summarized the available genetic mouse models displaying behavioural phenotypes relevant to the 'triad' of core symptoms in ASD and the most common assays used in mouse models to assess (Jiang et al., 1998; Yashiro et al., 2009; Greer et al., 2010; Mulherkar and Jana 2010; Kaphzan et al., 2012) ASD features. The phenotypic traits of mice carrying mutations in genes associated with ASD are reviewed in Ey et al. (2011) . Moreover, the curated web-based database AutDB (http://autism.mindspec.org) gives information about ASD genetics and biology in humans and mouse models, providing a platform for data mining, bioinformatics and computational biology (Kumar et al., 2011) . The most obvious shortcomings of using mouse models in studies of ASD include the inability to measure the major diagnostic behavioural symptoms, such as literal use of language, difficulty in interpreting irony or sarcasm and empathy. Furthermore, comparisons between ASD mouse models and ASD patients have been complicated due to species differences in the investigated animal strains. Also, studies in humans have been predominately carried out on peripheral tissues and body fluids and most animal studies have been performed using central nervous system tissues. These factors make cross-species translation of the findings difficult.
We suggest that establishing a comprehensive proteome map of both central and peripheral tissues in ASD will contribute to improving our understanding of affected pathways and may provide opportunities for novel pharmacological targets. These studies should be designed to account for the various subtypes of ASD, including the idiopathic and symptomatic forms. Also, the construction of a mouse model with a comprehensive molecular readout that overlaps with distinct forms of human ASD in the brain and periphery would facilitate the current and future objectives. Table 5 shows a list of the existing mouse models which meet some of these requirements, albeit only to a certain degree. The highlighted mouse models have been characterized at the molecular, functional and behavioural levels by different researchers. The major common changes seen in these models are an increase in serotonin and a decrease in GABA.
Cellular models
Although animal models have added to our understanding of the underlying causes of psychiatric conditions such as ASD, the development of these models is time consuming, expensive and requires an understanding of the genetic underpinnings of the corresponding diseases (Silverman et al., 2010) . Therefore, cellular model systems have also been developed for use in studies of these diseases, such as human embryonic stem cells (hESCs), peripheral blood mononuclear cells (PBMCs) and induced pluripotent stem cells (iPSCs). It is anticipated that the use of such models eliminates the problems associated with cross-species translation. Moreover, the cells can be derived directly from patients, which provides a unique opportunity to investigate the disease mechanisms more directly than can be achieved using animal models. Using hESCs is controversial due to the need for earlystage embryonic material (Thomson et al., 1998) .
Therefore, alternative approaches have been developed to generate human cells from adult subjects, including PBMCs and iPSCs. These new techniques have many advantages over the use of either post-mortem neural progenitor cells or hESCs, including greater availability of well-characterized subjects available for study (Liu et al., 2012) . However, critical evaluation will be essential to determine whether such cells can offer a viable surrogate of brain function and a suitable alternative to the use of animal models in the study of ASD or other psychiatric disorders.
Peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMCs) are primarily lymphocytes and monocytes obtained from peripheral blood by differential gradient centrifugation methods. PBMCs have proven useful in studies of brain disorders considering that they express most of the neurotransmitter receptors found in the central nervous system (Gladkevich et al., 2004; Marazziti et al., 2010; Sarkar et al., 2010) . This also makes them potentially useful as models for drug discovery. Several studies have now used PBMCs to investigate the pathology underlying ASD, mainly concerning immunological responses (Jyonouchi et al., 2001 (Jyonouchi et al., , 2002 (Jyonouchi et al., , 2005 (Jyonouchi et al., , 2008 (Jyonouchi et al., , 2011 (Jyonouchi et al., , 2012 Molloy et al., 2006; Ashwood et al., 2009 Ashwood et al., , 2011 Onore et al., 2009; Rose et al., 2012b; Siniscalco et al., 2012) , measles virus reaction (Kawashima et al., 2000; D'Souza et al., 2006; Baird et al., 2008) and β-endorphin levels (Brambilla et al., 1997; Cazzullo et al., 1999) . The main difference in ASD PBMCs compared to control PBMCs have been identified as altered levels of cytokines and inflammation-related factors such as CCL7 (Jyonouchi et al., 2011 (Jyonouchi et al., , 2012 , TNF-α (Jyonouchi et al., 2001 (Jyonouchi et al., , 2002 (Jyonouchi et al., , 2005 (Jyonouchi et al., , 2011 (Jyonouchi et al., , 2012 Ashwood et al., 2009 Ashwood et al., , 2011 ) , IL-10 (Jyonouchi et al., 2001 , 2002 Molloy et al., 2006; Ashwood et al., 2011) , IL-1β (Jyonouchi et al., 2001 (Jyonouchi et al., , 2005 (Jyonouchi et al., , 2008 (Jyonouchi et al., , 2011 (Jyonouchi et al., , 2012 Ashwood et al., 2011) , IL-23 (Jyonouchi et al., 2008 (Jyonouchi et al., , 2011 (Jyonouchi et al., , 2012 Onore et al., 2009 ) and IL-6 (Jyonouchi et al., 2001 (Jyonouchi et al., , 2005 (Jyonouchi et al., , 2011 (Jyonouchi et al., , 2012 Ashwood et al., 2009 Ashwood et al., , 2011 , with no differences found for IL-2 (Molloy et al., 2006; Ashwood et al., 2011) and measles antibody (D'Souza et al., 2006; Baird et al., 2008 ) (see Table 6 ). However, in all of these studies, PBMCs were stimulated with immunogenic adjuvants, such as phytohaemagglutinin (PHA), tetanus or lipopolysaccharide (LPS), which causes different reactions of immune markers. Hence, assessing the molecular and immune profiles of PBMCs isolated from ASD patients with or without a pro-inflammatory status might lead to new insights into the role of the immune system in disease development and response to treatment.
Induced pluripotent stem cells
Induced pluripotent stem cells (iPSCs) are predominantly obtained from fibroblasts, and can subsequently be differentiated to specific cell types such as neurons and glial cells. As with PBMCs, they can be directly obtained from patients and, therefore, have potential for direct translation to the human disease. Furthermore, iPSCs are morphologically identical to embryonic stem (ES) cells and display similar gene expression profiles and phenotypic markers (Yamanaka and Blau, 2010) . Neuronal cultures derived from iPSCs can be used to investigate disease phenotypes and molecular disease pathology, and there is also potential that they can be used for drug screening (Marchetto et al., 2010; Sheridan et al., 2011) . New techniques have also emerged which can derive iPSCs from cells in blood (DeRosa et al., 2012) and urine (Zhou et al., 2012) , which is less invasive than the skin punch biopsy approach that is generally used in fibroblast generation. To generate iPSCs from these starting materials the somatic cells are genetically reprogrammed into a pluripotent state by viral vector introduction of stem cell transcription factors (Lowry et al., 2008; Park et al., 2008; Zhou et al., 2009) . After this, the cells can be differentiated into neurons and glial cells (Marchetto et al., 2011; Robinton and Daley, 2012) . The current challenge of iPSCs is the demonstration of disease-specific pathogenesis and phenotypic rescue in relevant cell types (Marchetto et al., 2011) .
The use of neuronal cells derived from iPSCs in disorders linked to ASD has been reviewed in Chailangkarn et al. (2012) and Kim et al. (2012) . The main differences indicated between patient iPSC-derived neuronal cells and controls are a reduced soma size in Rett syndrome (RTT) (Marchetto et al., 2010; Cheung et al., 2011) , fewer and shorter neurites and increased numbers of glial fibrillary acidic protein (GFAP) cells in FXS (Urbach et al., 2010; Sheridan et al., 2011 ) and a defect in Ca 2+ signalling and abnormal norepinephrine and dopamine production in Timothy syndrome (TS) (Pasca et al., 2011; Chailangkarn et al., 2012; Kim et al., 2012) . However, none of these iPSC lines were derived from patients diagnosed solely with ASD. Up to now, one specific ASD iPSC cell line has been developed, and this was produced from patient lymphocytes (DeRosa et al., 2012) . However, studies comparing these ASD-iPSCs with control iPSCs have yet to be performed.
Conclusion and future directions
Investigations to understand the affected pathways in ASD have been carried out mainly using behavioural, genetic and proteomic methods. These investigations have studied the effects of ASD in tissues and body fluids, such as brain, CSF, plasma and serum, of both humans and animal models. However, the comparison between human and animal models in ASD is difficult due to the inherent problem of translation. Moreover, genetics studies have been carried out extensively in both human and animal studies, whereas proteomic, transcriptomic and biochemical studies have been less frequent. Furthermore, there have only been a few attempts to dissect the molecular profiles associated with the various subtypes of ASD, including the idiopathic or symptomatic forms. Dissecting ASD heterogeneity and taking into account the various co-morbidities should be the primary focus of investigations in the immediate future. It will also be essential to obtain a better understanding Table 6 . Main proteins changed in autism spectrum disorder peripheral blood mononuclear cells
Marker General effect
Number of studies Articles CCL7 3 , 0 , 0 ↔ 2, same author (Jyonouchi et al., 2011 (Jyonouchi et al., , 2012 ) GM-CSF 1 , 1 , 2 ↔ 2, same author ) IFNγ 4 , 3 , 4 ↔ 7 ((Jyonouchi et al., 2001 , 2002 Molloy et al., 2006; Ashwood et al., 2011 ) IL-10 2 , 11 , 7 ↔ 7 (Jyonouchi et al., 2001 Molloy et al., 2006; Ashwood et al., 2011 ) IL-12 4 , 6 , 4 ↔ 4 (Jyonouchi et al., 2005 Ashwood et al., 2011 Jyonouchi et al., 2001 Jyonouchi et al., , 2002 Jyonouchi et al., , 2011 Molloy et al., 2006; Ashwood et al., 2011) IL-6 3 , 9 , 2 ↔ 6 (Jyonouchi et al., 2001 (Jyonouchi et al., , 2005 (Jyonouchi et al., , 2011 (Jyonouchi et al., , 2012 Ashwood et al., 2009 Ashwood et al., , 2011 (Jyonouchi et al., 2001 (Jyonouchi et al., , 2005 (Jyonouchi et al., , 2008 ) TNF-α 14 , 4 , 2 ↔ 7 (Jyonouchi et al., 2001 (Jyonouchi et al., , 2002 (Jyonouchi et al., , 2005 (Jyonouchi et al., , 2011 (Jyonouchi et al., , 2012 Ashwood et al., 2009 Ashwood et al., , 2011 of the underlying causes of the disease by investigating possible effects on synapse formation, myelination or hormonal biogenesis and secretion in the context of different ASDs. Biomarker profiling studies in plasma and serum have already established that there are effects on hormones and growth factors involved in regulation of whole-body metabolism and immune function in ASD, with potential gender-related effects (Schwarz et al., 2010) . Also, researchers should take into account other potential factors involved in disease heterogeneity, such as differences in developmental stage, immunological effects and metabolic status. This could also be used as a means of patient stratification through pre-screening prior to treatment with novel compounds, when these are developed. In order to guide the way to an integrated understanding of the mechanism of ASD and to improve translatability of preclinical models, there is an increasing trend towards usage of more comprehensive approaches using tissues and cellular models which have been obtained directly from subjects with different subtypes of ASD. However, these still require validation before incorporation into clinical studies or the drug discovery pipeline. Only the creation of a comprehensive molecular biomarker pattern for subtype-defined human and preclinical models will draw a final conclusion about the best representative ASD models. This could pave the way for a novel drug discovery paradigm aimed at identifying compounds which target specific molecular pathways and treat the actual symptoms of ASD.
